Welcome to our dedicated page for IN8BIO SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IN8bio, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers. Form 8-K reports cover operating and financial results, clinical updates for INB-200 and INB-400 in newly diagnosed glioblastoma, preclinical γδ T cell engager data, financing and capital-structure matters, and governance events.
Proxy materials describe annual-meeting voting matters, director elections, auditor ratification, equity incentive plan proposals, board oversight, executive compensation, and stockholder governance. The filings also identify INAB common stock registered on Nasdaq and provide formal records of material events affecting the company's pipeline, financing, and corporate governance.
IN8BIO, Inc. received an amended ownership report from Laurence W. Lytton and the Lytton-Kambara Foundation detailing their beneficial position in the company’s common stock. Each reporting person beneficially owns 1,056,513 shares of common stock (including warrants), representing 9.99% of the class based on 9,847,089 shares outstanding as of May 4, 2026. The position consists of 327,892 shares of common stock and warrants to purchase 1,092,753 shares, all subject to a 9.99% beneficial ownership limitation. Both Lytton and the Foundation report shared voting and dispositive power over the same shares and no sole voting or dispositive power.
IN8bio, Inc., a clinical-stage gamma-delta T cell immunotherapy company, reported a net loss of $4.8 million for the quarter and $9.9 million for the six months ended June 30, 2026, modestly improved from the prior-year periods as both research and development and general and administrative expenses declined slightly.
Cash and restricted cash totaled $18.1 million at June 30, 2026, with net cash used in operating activities of $8.7 million in the first half. Management states that existing cash of $18.0 million is expected to fund operations only into April 2027 and explicitly notes substantial doubt about the company’s ability to continue as a going concern without additional capital.
The pipeline centers on INB-100 for high‑risk leukemias, DeltEx DRI candidates INB-200/400 for glioblastoma, and the INB-600 T cell engager platform, including INB-619 for CD19‑positive autoimmune disease. Future funding may come from equity or debt financing, strategic collaborations, and up to $29.1 million of potential warrant and milestone proceeds, none of which are assured.
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on γδ T cell therapies, reported results for the second quarter ended June 30, 2026. The company recorded a net loss of $4.8 million, or $0.25 per share, compared with a net loss of $5.1 million, or $1.24 per share, a year earlier. Research and development expenses were $2.5 million and general and administrative expenses were $2.4 million. Cash was $18.0 million as of June 30, 2026, compared with $13.2 million in the prior-year period.
IN8bio highlighted progress across its pipeline, including advancing INB-619, a CD19-targeting γδ T cell engager, into IND-enabling studies, with initial in vivo preclinical data expected in the second half of 2026. Updated data from the DeltEx DRI glioblastoma program showed median progression-free survival of 13.0 months versus 6.6 months for standard-of-care and median overall survival exceeding 19.5 months versus 13.2 months. Additional translational analyses showed an 18-fold increase in intratumoral CD8+ T cells and a 90% reduction in immunosuppressive granulocytes after repeated DeltEx DRI dosing.
IN8bio, Inc. has put a new at-the-market stock offering program in place and ended its prior one. On June 1, 2026, the company entered into a Capital on Sales Agreement with JonesTrading Institutional Services, allowing IN8bio to issue and sell common stock from time to time at its sole discretion under its existing Form S-3 shelf registration. JonesTrading will use commercially reasonable efforts to sell any shares and will earn a 3.0% commission on gross sales proceeds, while IN8bio has no obligation to sell any stock and either party can terminate the agreement on written notice.
The company also terminated its earlier Controlled Equity Sales Agreement with Cantor Fitzgerald & Co., effective May 29, 2026. Both parties waived the original advance notice requirements, and IN8bio is not subject to any termination penalties. After this termination, no additional shares may be issued or sold under the Cantor agreement or its related prospectus.
IN8bio, Inc. is registering an at-the-market offering to sell up to $2,800,000 aggregate offering price of its common stock through JonesTrading Institutional Services LLC under a Sales Agreement. Sales may occur from time to time at prevailing market prices; JonesTrading will act as agent (or principal) and receive 3.0% of gross proceeds as compensation.
The prospectus supplement ties the offering to our existing Form S-3 shelf and states shares outstanding were 9,847,089 as of March 31, 2026. The filing discloses the aggregate market value of common stock held by non-affiliates as $17,932,668 as of June 1, 2026 (based on 9,589,662 non-affiliate shares at $1.87). Proceeds, if any, are intended for clinical development, working capital and general corporate purposes.
IN8bio, Inc. investors Emily and Malcom Fairbairn amended their Schedule 13D to report a major reduction in ownership. Their charitable remainder unitrust (CRUT) transferred 724,637 shares of common stock to a 501(c)(3) foundation for no consideration on May 27, 2026.
After this transfer, Emily Fairbairn beneficially owns 215,431 shares, or 2.2% of IN8bio’s outstanding common stock, and Malcom Fairbairn beneficially owns 205,626 shares, or 2.1%. The CRUT itself beneficially owns 202,582 shares, also 2.1%, based on 9,847,089 shares outstanding as of May 4, 2026. The reporting persons state they ceased to be beneficial owners of more than five percent on May 27, 2026.
IN8BIO, INC. director Emily Fairbairn reported an indirect transfer of common stock. On May 27, 2026, an entity associated with her made a bona fide gift of 724,637 shares of common stock at $0.00 per share to a 501(c)(3) charitable foundation. After this gift, she continued to report indirect holdings of 923 shares through the Malcom and Emily Fairbairn 2010 CRUT and 3,044 shares through Valley High Limited Partnership, while the Roth IRA account that made the gift reported no remaining shares.
IN8bio, Inc. filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration to update disclosures and file an updated auditor consent. The prospectus covers the offer and sale, from time to time, of up to $200,000,000 of common stock, preferred stock, debt securities, warrants, rights and units.
The shelf permits offerings in one or more combinations and will be supplemented by prospectus supplements that set specific terms, pricing and distribution methods. The company’s common stock trades on the Nasdaq Capital Market under the symbol INAB (last reported sale $1.49 per share on May 15, 2026). The prospectus states net proceeds are intended for working capital and general corporate purposes, and discloses an aggregate market value of common stock held by non-affiliates of $17,631,022 (based on 8,815,511 non-affiliate shares at $2.00 per share on March 20, 2026).
IN8BIO, INC. CEO William Tai-Wei Ho received an employee stock option grant covering 154,500 shares of common stock at an exercise price of $1.58 per share. The option expires on May 9, 2036 and represents compensation, not an open-market purchase.
The award vests in four equal installments of 25% each on November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, contingent on the CEO continuing to provide service through each vesting date.